Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2017

View Archived Issues

Arcus Biosciences completes series C financing, begins two clinical trials

OX1 receptor antagonist C4X_3256 demonstrates efficacy in nicotine dependence rat model

Preclinical results for PF-3628, a new non-catechol D1 receptor agonist for schizophrenia

Clinical progress reported for Pfizer's IRAK-4 inhibitor PF-06650833

CRISPR Therapeutics, Casebia Therapeutics and CureVac form gene-editing program collaboration

EMA committee supports approval of Endoceutics' Intrarosa

FDA approves Allergan's sNDA for Vraylar

European Commission grants marketing authorization for self-injectable formulation of Benlysta

Bayer and Loxo Oncology collaborate to develop and commercialize highly selective TRK inhibitors

Certainty Therapeutics to develop CAR-T technology from Wistar Institute

Dosing begins in first-in-human phase Ib study of DEN-181

EC approves Faslodex in combination with palbociclib for HR+, HER2- breast cancer

EMA's CHMP issues positive opinion on Adcetris for CTCL

Phase II study of topical radezolid for acne begins

FDA approves Fasenra for severe eosinophilic asthma

EMA grants Motrem access to PRIME scheme for septic shock

Discovery of novel orally bioavailable CDK12 covalent inhibitors at Aurigene

Achillion reports preliminary data from phase II study of ACH-4471 in C3G

Boehringer Ingelheim's adalimumab biosimilar, Cyltezo, approved in E.U.

Novel IAP antagonists identified at Medshine Discovery

Everon Biosciences describes compounds to remove senescence-associated macrophages

BeiGene begins pivotal trials for BGB-3111

Astar Biotech divulges novel tyrosine kinase Bcr-Abl inhibitors

Monopar Therapeutics acquires phase II cancer drug candidate

The University of Texas discovers novel sigma1/2 receptor antagonists

New yohimbine analogues synthesized at the University of Florida

First commercial launch for Fotivda

Otsuka offers overview of third quarter 2017

First-in-human results provided for TR-Pharm's anti-interleukin-1 biologic RPH-104

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...